Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK3335065
- Development stage
- Phase 1
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
GSK3335065 is a small molecule inhibitor of kynurenine monooxygenase (KMO) that was developed by GSK for the treatment of acute pancreatitis. The drug acts by blocking KMO, thereby reducing levels of 3-hydroxykynurenine (3HK) and other related metabolites in the tryptophan pathway, which are elevated in patients with acute pancreatitis. The compound was administered intravenously in early clinical studies to assess safety, tolerability, pharmacokinetics, and pharmacodynamics. Although partial inhibition of KMO activity was observed in humans consistent with preclinical findings, development was discontinued after a serious adverse event occurred during a phase 1 trial[1][4][6].
- Other names
- KMO inhibitor (Kynos Therapeutics)Kynurenine 3-monooxygenase inhibitor (Kynos Therapeutics)
02
Targets
KMO (Kynurenine 3-monooxygenase)
Beyond the preview
Go deeper on GSK3335065.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSK3335065.